|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash and due from banks | |||||||||||||||
| Interest-earning deposits with banks | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Securities available-for-sale, at fair value | |||||||||||||||
| Restricted stock, at cost | |||||||||||||||
| Loans held-for-sale, at fair value | |||||||||||||||
| Loans | |||||||||||||||
| Allowance for credit losses | |||||||||||||||
| Net loans | |||||||||||||||
| Other real estate owned | |||||||||||||||
| Premises and equipment, net | |||||||||||||||
| Accrued interest receivable | |||||||||||||||
| Intangible assets | |||||||||||||||
| Goodwill | |||||||||||||||
| Company-owned life insurance | |||||||||||||||
| Other assets | |||||||||||||||
| Total Assets | |||||||||||||||
| Liabilities and Shareholders’ Equity | |||||||||||||||
| Liabilities | |||||||||||||||
| Non-interest-bearing deposits | |||||||||||||||
| Interest-bearing deposits | |||||||||||||||
| Total deposits | |||||||||||||||
| Borrowed funds | |||||||||||||||
| Short-term borrowings | |||||||||||||||
| Subordinated debentures, net | |||||||||||||||
| Subordinated debentures owed to unconsolidated subsidiary trusts, net | |||||||||||||||
| Accrued interest and other liabilities | |||||||||||||||
| Total Liabilities | |||||||||||||||
| Shareholders’ Equity | |||||||||||||||
| Preferred stock and related surplus, $1.00 par value per share; 2,000,000 shares authorized; 1,500 shares issued and outstanding at September 30, 2026; 1,500 shares issued and outstanding at December 31, 2025 | |||||||||||||||
| Common Stock $0.50 par value; 40,000,000 shares authorized, 20,764,929 shares issued and 20,193,639 shares outstanding at September 30, 2026; 40,000,000 shares authorized, 15,599,814 shares issued and 15,028,524 shares outstanding at December 31, 2025 | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Common stock, additional paid-in capital | |||||||||||||||
| Retained earnings | |||||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||||
| Treasury stock 571,290 shares, at cost, at September 30, 2026, and 571,290 shares, at cost, at December 31, 2025 | |||||||||||||||
| Total Shareholders’ Equity | |||||||||||||||
| Total Liabilities and Shareholders’ Equity | |||||||||||||||
Loading...